מדינה: קנדה
שפה: אנגלית
מקור: Health Canada
CISATRACURIUM (CISATRACURIUM BESYLATE)
FRESENIUS KABI CANADA LTD
M03AC11
CISATRACURIUM
2MG
SOLUTION
CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG
INTRAVENOUS
10X10ML
Prescription
NEUROMUSCULAR BLOCKING AGENTS
Active ingredient group (AIG) number: 0133260001; AHFS:
APPROVED
2015-07-16
PRODUCT MONOGRAPH PR CISATRACURIUM BESYLATE INJECTION SINGLE-DOSE Solution for injection (preservative-free) 2 mg/mL cisatracurium PR CISATRACURIUM BESYLATE INJECTION MULTI–DOSE Solution for injection (preserved) 2 mg/mL cisatracurium Non-depolarizing Skeletal Neuromuscular Blocking Agent THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED PROFESSIONALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS. FRESENIUS KABI CANADA LTD. 45 Vogell Road, Suite 200 Richmond Hill, ON L4B 3P6 Canada Date of Preparation: July 7, 2015 Control Number 184996 _ _ _Cisatracurium-PM-ENG-v1.0_ _ _ _Page 2 of 37_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ..................................................................................................11 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................13 OVERDOSAGE ................................................................................................................20 ACTION AND CLINICAL PHARMACOLOGY ............................................................20 STORAGE AND STABILITY ..........................................................................................27 SPECIAL HANDLING INSTRUCTIONS .......................................................................28 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................2 קרא את המסמך השלם